Polen 5Perspectives Small Growth Portfolio Performance & Attribution

The Portfolio returned -1.3% gross and -1.5% net compared to the 1.2% return of the Russell 2000 Growth Index. Bloom Energy announced better than expected results with added optimism from a $5B partnership with Brookfield as the preferred onsite power provider. GeneDx delivered better-than-expected results—including raised full-year guidance—driven by a significant year-over-year increase in high value testing volumes.

Seeking Alpha • Feb 5, 2026

GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced it will release financial results for the fourth quarter of 2025 before the market opens on Monday, February 23, 2026.

Business Wire • Feb 3, 2026

Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders. If you currently own GeneDx stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your le.

Business Wire • Jan 15, 2026

GeneDx: Fundamentals Intact Though Q4 Results Pause Near Term Momentum

GeneDx Holdings Corp. is positioned as a leader in advanced exome and genome diagnostics, leveraging its expanding rare disease dataset. Fourth quarter preliminary results met guidance but did not exceed it sufficiently for a high multiple stock, resulting in a pullback. Company's 2026 guidance was strong and above expectations with testing volume growth of 33-35%.

Seeking Alpha • Jan 14, 2026

GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 15, 2026

Why is GeneDx stock crashing on Monday?

GeneDx stock (NASDAQ: WGS) plunged 14% on Monday after the genomics testing company released preliminary full-year 2025 results that met expectations. But the company unveiled 2026 guidance that investors deemed disappointingly conservative, wiping out significant gains and reigniting concerns about the high-growth biotech's ability to maintain breakneck expansion.

Invezz • Jan 12, 2026

GeneDx Partners With Komodo Health to Advance Rare Disease Research

WGS collaborates with Komodo Health to link genomic data with real-world insights, expanding data monetization and strengthening its role in rare disease research.

Zacks Investment Research • Jan 12, 2026

GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx reported high growth and profitability in preliminary results for the fourth quarter and full year of 2025 and issued 2026 guidance.

Business Wire • Jan 12, 2026

GeneDx and Komodo Health Partner to Build the World's Most Complete Longitudinal Rare Disease Dataset

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Komodo Health Partner to Build the World's Most Complete Longitudinal Rare Disease Dataset.

Business Wire • Jan 8, 2026

GeneDx Announces GenomeDx Prenatal™, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced GenomeDx Prenatal™, a whole genome sequencing test that delivers fast, comprehensive insights when fetal anomalies are identified.

Business Wire • Jan 7, 2026